Trovagene, US Oncology Research Announce Clinical Study Agreement

Trovagene (NASDAQ: TROV ) and US Oncology Research announced today that they have entered into a Clinical Study Agreement to examine the utility of quantitative urine-based KRAS mutation detection and monitoring in pancreatic cancer patients. US Oncology Research draws from a network of experienced investigators and clinical staff who